^
    17h
    Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma （SPARE-01） (clinicaltrials.gov)
    P2, N=30, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Trial completion date: Dec 2023 --> Dec 2027 | Trial primary completion date: Apr 2023 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Focus V (anlotinib)
    22h
    COSMIC-312: Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy (clinicaltrials.gov)
    P3, N=837, Active, not recruiting, Exelixis | Trial completion date: Dec 2024 --> Jul 2026
    Trial completion date
    |
    Tecentriq (atezolizumab) • sorafenib • Cabometyx (cabozantinib tablet)
    1d
    Targeting CXCR6 Disrupts β-Catenin Signaling and Enhances Sorafenib Response in Hepatocellular Carcinoma. (PubMed, Cancers (Basel))
    CXCR6 antagonism with SBI-457 can modulate β-catenin activation and may help overcome sorafenib resistance in selected HCC models. These findings support further development of CXCR6 antagonists as single agents or combination therapies to improve treatment outcomes in HCC.
    Journal
    |
    CXCR6 (C-X-C Motif Chemokine Receptor 6)
    |
    sorafenib
    3d
    Lysophosphatidic acid-induced Arf6-driven macropinocytosis of CD147+ extracellular vesicles promotes sorafenib resistance of hepatocellular carcinoma. (PubMed, Int J Biol Sci)
    Importantly, inhibition of LPA-Arf6-mediated EV macropinocytosis significantly improves the sorafenib efficacy. Our findings uncover a previously unrecognized mechanism mediated by differential TME and CD147⁺ EV macropinocytosis in HCC and highlight the LPA-Arf6-macropinocytosis as a novel targeting axis to overcome SFR in HCC.
    Journal
    |
    EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1) • ANXA5 (Annexin A5) • BSG (Basigin (Ok Blood Group))
    |
    sorafenib
    3d
    Sorafenib as first-line therapy for metastatic uveal melanoma: A multicenter, placebo-controlled randomized discontinuation study (STREAM). (PubMed, iScience)
    The detection of GNAQ/GNA11 mutations in ctDNA at baseline was associated with an inferior outcome. (ClinicalTrials.gov: NCT01377025).
    Journal
    |
    GNAQ (G Protein Subunit Alpha Q) • GNA11 (G Protein Subunit Alpha 11)
    |
    sorafenib
    4d
    Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatment of Elderly Patients With Small Cell Lung Cancer/ Open-label, Single-arm, Exploratory Phase II Clinical Study (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting --> Active, not recruiting | Trial completion date: May 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Focus V (anlotinib) • etoposide oral • Enweida (envafolimab)
    4d
    TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens (clinicaltrials.gov)
    P2, N=21, Completed, First Affiliated Hospital, Sun Yat-Sen University | Not yet recruiting --> Completed | Phase classification: PN/A --> P2
    Trial completion • Phase classification
    |
    Stivarga (regorafenib) • irinotecan
    4d
    A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis (clinicaltrials.gov)
    P=N/A, N=2000, Active, not recruiting, Boehringer Ingelheim | Initiation date: Jun 2023 --> Jun 2025
    Trial initiation date
    |
    cyclophosphamide • nintedanib • Actemra IV (tocilizumab)
    4d
    A Macrophage-Derived 7-Gene Signature Predicts Prognosis and Therapeutic Response in Hepatocellular Carcinoma. (PubMed, IUBMB Life)
    Conversely, the high-risk group exhibited distinct genomic features and was predicted to be more sensitive to specific targeted agents, including Navitoclax and Sorafenib. We identified and validated a novel 7-gene prognostic signature derived from a subpopulation of EGFR-TKI-resistant macrophages. This signature accurately predicts patient survival, offers insights into the molecular mechanisms of therapy resistance in HCC, and provides a promising tool for improved patient stratification and the development of personalized treatment strategies.
    Journal • Gene Signature • IO biomarker
    |
    FAM83D (Family With Sequence Similarity 83 Member D) • PPM1G (Protein Phosphatase, Mg2+/Mn2+ Dependent 1G) • SLC41A3 (Solute Carrier Family 41 Member 3)
    |
    sorafenib • navitoclax (ABT 263)
    7d
    Using single-cell and transcriptome data to identify prognostic genes associated with SUMO-ylation and their molecular regulatory mechanisms in breast cancer. (PubMed, BMC Cancer)
    In this study, 8 SUMO-ylation related prognostic genes were identified in BRCA, namely GPC1, CAPZA1, NUDCD1, MTDH, COX7A1, PLK3, FAM43A and CEBPD, offering fresh perspectives on the prognosis of BRCA.
    Journal • BRCA Biomarker
    |
    CD8 (cluster of differentiation 8) • BRCA (Breast cancer early onset) • GPC1 (Glypican 1) • FAM43A (Family With Sequence Similarity 43 Member A) • MTDH (Metadherin)
    |
    sorafenib • Zarnestra (tipifarnib)
    7d
    Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial. (PubMed, Lancet Gastroenterol Hepatol)
    These findings suggest that tinengotinib might have activity in patients with cholangiocarcinoma with FGFR2 fusions that progressed following FGFR inhibitor therapy. Anti-tumour activity was also observed in patients with other FGFR alterations. The data from this phase 2 study supported the initiation of a phase 3 registration trial.
    P2 data • Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 mutation • FGFR2 fusion
    |
    Lytgobi (futibatinib) • Pemazyre (pemigatinib) • tinengotinib (TT-00420)
    7d
    REPLICA: Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC) (clinicaltrials.gov)
    P=N/A, N=150, Active, not recruiting, Ipsen | Recruiting --> Active, not recruiting | Trial completion date: Sep 2027 --> Mar 2027
    Enrollment closed • Trial completion date
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet)